By now, most of you have seen the phenomenal news on the leukemia study that has been lighting up the airwaves. The articles are based on research performed by Drs. Carl June and Michael Kalos at the University of Pennsylvania who published their results in Science Translational Medicine and the New England Journal of Medicine.
A potential cure for leukemia is incredible. Even more incredible, these researchers are Adaptive clients who used the ImmunoSEQ technology in their study. The following is the acknowledgment in the STM paper:
“We are grateful to C. Desmarais and H. Robins at Adaptive TCR for their excellent assistance with IgH immune profiling, which was performed as a service by ImmunoSEQ (http://www.immunoseq.com), a division of Adaptive TCR Corp. Additionally, ImmunoSEQ provided a cloud-based suite of computational analysis tools (ImmunoSEQ Analyzer) that we used for data interpretation.”
I attach the MSNBC and NY Times articles for those of you that have not seen it:
http://www.msnbc.msn.com/id/
http://www.nytimes.com/2011/
